| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 269 | 684 | 219 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit/Loss - EUR | -269 | -684 | -219 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit/Loss - EUR | -269 | -684 | -219 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Encore Enterprise Pharmaceutical Company Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 691 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 225 | 223 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 225 | 223 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders Funds | -44 | -728 | -934 | -917 | -899 | -882 | -863 | -865 | -863 | -858 |
| Social Capital | 225 | 223 | 219 | 215 | 211 | 207 | 202 | 203 | 202 | 201 |
| Debts | 960 | 950 | 934 | 917 | 899 | 882 | 863 | 865 | 863 | 858 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2110 - 2110" | |||||||||
| CAEN Financial Year |
2110
|
|||||||||
Comments - Encore Enterprise Pharmaceutical Company Srl